Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. (KLRS): 5 pipeline candidates · ~25 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
24.6 months
D/E 0.60 · 3% dilution
Lead: Approved
5 candidates
N/A
1 buy · 1 sell (180d)
A transparent, data-derived signal for Kalaris Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$105.6M
Cash
$34.9M
Quarterly Burn
$11.6M
Runway
24.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| alvr106 | Phase 1 |
| alvr107 | Preclinical |
| for geographic atrophy | Approved |
| posoleucel | Phase 3 |
| th103 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
53
Total value held
$98.1M
| Holder | Shares | Value |
|---|---|---|
| samsara biocapital, llc | 12,948,081 | $74.7M |
| rtw investments, lp | 1,300,000 | $7.5M |
| alyeska investment group, l.p. | 572,687 | $3.3M |
| vanguard capital management llc | 510,696 | $2.9M |
| woodline partners lp | 200,000 | $1.2M |
| raymond james financial inc | 118,887 | $686K |
| goldman sachs group inc | 110,503 | $638K |
| adar1 capital management, llc | 100,000 | $577K |
| whi trust co llc | 97,493 | $563K |
| boothbay fund management, llc | 92,261 | $532K |
Showing top 10 of 53 institutional holders of Kalaris Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Kalaris Therapeutics, Inc.'s pipeline?
Kalaris Therapeutics, Inc. (KLRS) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kalaris Therapeutics, Inc.'s lead drug candidate?
Kalaris Therapeutics, Inc.'s most advanced tracked candidate is alvr106 (Phase 1) for respiratory diseases caused by human metapneumovirus, influenza, parainfluenza virus, and respiratory syncytial virus.
What is Kalaris Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kalaris Therapeutics, Inc. has approximately 24.6 months of cash runway.
What is Kalaris Therapeutics, Inc.'s market capitalization?
Kalaris Therapeutics, Inc.'s market capitalization is approximately $105.6M.
Who is the CEO of Kalaris Therapeutics, Inc.?
Mr. Andrew Oxtoby is the chief executive officer of Kalaris Therapeutics, Inc. (KLRS).
Get the full picture on Kalaris Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.